Table 4.

¹⁸F-fluciclovine uptake in patients with progressive versus non-progressive mCRPC

Parameters	Progressive Disease	Non-Progressive Disease	p-value
Mean SUVmax (summed)
Baseline	59.5±1.4	43.0±16.9	0.09
Post-cycle 1	57.1±3.0	44.5±23.8	0.31
Post-cycle 6	61.0	28.1±6.4	0.04
Mean SUVmean (summed)
Baseline	37.3±1.7	28.1±11.3	0.15
Post-cycle 1	36.0±0.4	30.1±15.8	0.46
Post-cycle 6	37.1	18.7±3.7	0.04
SUVpeak hottest lesion
Baseline	7.0±2.1	5.6±2.2	0.14
Post-cycle 1	9.0±3.8	5.3±1.9	0.42
Post-cycle 6	9.8	4.5±1.0	<0.04